This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
2025-04-18 13:00:00
Artificial intelligence is increasingly being adopted in various sectors including pharmaceuticals. The U.S. FDA’s decision to phase out animal testing in favor of AI-based methods利好生物技术公司Recursion Pharmaceuticals,该公司已开始利用AI进行药物开发。尽管其股价因这一消息上涨,但过去12个月表现仍不佳。Recursion通过与Nvidia合作建立了大型AI超级计算机,并声称能显着减少药物研发时间和成本,从而提高制药公司的收益和利润空间。然而,由于缺乏实际成果和临床进展,该公司面临的风险依然存在,且其他公司也可能加速其自身的AI研究。尽管有合作伙伴支持,但风险规避型投资者应谨慎对待Recursion Pharmaceuticals的股票。